Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dimitrios C. Ziogas, Evangelos Terpos, Maria Gavriatopoulou, Magdalini Migkou, Despoina Fotiou, Maria Roussou, Nikolaos Kanellias, Ioanna Tatouli, Evangelos Eleutherakis-Papaiakovou, Ioannis Panagiotidis, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis & Meletios A. Dimopoulos. (2018) Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leukemia & Lymphoma 59:4, pages 983-987.
Read now
Read now
Reed Friend, Manisha Bhutani, Peter M Voorhees & Saad Z Usmani. (2017) Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma. Drug Design, Development and Therapy 11, pages 893-900.
Read now
Read now
Articles from other publishers (9)
Krishnakumar Rathnam, S. V. Saju & Susan Raju Honey. (2022) Management of Relapsed and Refractory Multiple Myeloma: Recent advances. Indian Journal of Medical and Paediatric Oncology 43:06, pages 458-472.
Crossref
Crossref
Li-Chung Tsao, Jeremy Force & Zachary C. Hartman. (2021) Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Research 81:18, pages 4641-4651.
Crossref
Crossref
Constantine S. Mitsiades. (2021) Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. Cold Spring Harbor Perspectives in Medicine 11:7, pages a034900.
Crossref
Crossref
Jakub Radocha, Niels W. C. J. van de Donk & Katja Weisel. (2021) Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers 13:7, pages 1571.
Crossref
Crossref
Mariko Ishibashi, Rimpei Morita & Hideto Tamura. (2021) Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma. Cancers 13:2, pages 279.
Crossref
Crossref
Sikander Ailawadhi, Kevin R. Kelly, Robert A. Vescio, Sundar Jagannath, Jeffrey Wolf, Mecide Gharibo, Taimur Sher, Leyla Bojanini, Maurice Kirby & Asher Chanan-Khan. (2019) A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:1, pages 29-34.
Crossref
Crossref
Mariko Ishibashi, Saori Soeda, Makoto Sasaki, Hiroshi Handa, Yoichi Imai, Norina Tanaka, Sakae Tanosaki, Shigeki Ito, Takeshi Odajima, Hiroki Sugimori, Toshio Asayama, Mika Sunakawa, Yuta Kaito, Ryosuke Kinoshita, Yasuko Kuribayashi, Asaka Onodera, Keiichi Moriya, Junji Tanaka, Yutaka Tsukune, Norio Komatsu, Koiti Inokuchi & Hideto Tamura. (2018) Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget 9:78, pages 34784-34793.
Crossref
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
H.Q. Zeng, Y. Luo, S.F. Lou, Q. Liu, L. Zhang & J.C. Deng. (2017) Silencing of augmenter of liver regeneration inhibited cell proliferation and triggered apoptosis in U266 human multiple myeloma cells. Brazilian Journal of Medical and Biological Research 50:10.
Crossref
Crossref